Blood Test
Finger prick test detects blood-based biomarkers of Alzheimer’s disease
A finger prick test measured blood-based biomarkers of Alzheimer’s disease and has potential to increase accessibility of testing, according to research at the Alzheimer’s Association International Conference.
Blood tests for AD pathology may improve diagnostic accuracy, treatment in primary care
Utilization of blood tests to detect Alzheimer’s pathology may boost diagnostic accuracy and treatment in a primary care setting, according to research presented at the Alzheimer’s Association International Conference.
Quanterix launches blood test to detect early Alzheimer’s disease
Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.
FDA grants 510(k) clearance for CSF assays to aid early Alzheimer’s diagnosis
The FDA has granted 510(k) clearance to Roche for its Elecsys beta-amyloid CSF II and total-tau CSF assays, designed to aid in the diagnosis of adults aged 55 and older being evaluated for Alzheimer’s disease.
Offering a blood test as a secondary option boosts CRC screening by nearly twofold
Compared with reoffering colonoscopy and fecal immunochemical test alone, offering a blood test as a secondary option resulted in a nearly twofold increase in colorectal cancer screening in veterans who had declined first-line screening.
Cell-free DNA blood test ‘poised to have significant impact’ on CRC screening
CHICAGO — A cell-free DNA blood-based test displayed 83% sensitivity for colorectal cancer detection and 90% specificity in an average-risk population, similar to the performance of current noninvasive screening options.
Blood test predicts AD pathology up to 10 years before symptoms
A new blood test may be able to detect Alzheimer’s disease-related pathology up to 10 years before symptoms appear, according to a press release from Durin Technologies.
FDA clears lab blood test for evaluating concussion
The FDA has cleared Abbott’s laboratory blood test for concussion, making it the first commercially available test of its kind, according to a company press release.
C₂N Diagnostics receives $15M to advance blood test for Alzheimer’s detection
CN Diagnostics announced it has received a $15 million program-related investment from GHR Foundation to support and advance the PrecivityAD2 blood test for the detection of Alzheimer’s disease.
Virtual reality intervention reduces pain, anxiety in kids during blood draws
A virtual reality intervention designed to distract children undergoing a blood draw significantly improved pain and anxiety, highlighting the possibility for virtual reality interventions for other procedures, according to researchers.